Home Diseases Aspergillosis

Aspergillosis is a fungal infection that occurs most commonly within the lung

Aspergillosis results in a range of diseases either directly from the infection, or from an allergic response. It can occur in a variety of organs, though the most common infection site is within the respiratory system.

The use of aggressive and intensive chemotherapeutic regimens, bone marrow and solid-organ transplantations, and the use of immunosuppressive regimens for treatment of autoimmune diseases, has led to significant increases in the prevalence of invasive fungal infections.

Disseminated candidiasis, pulmonary aspergillosis, and emerging opportunistic fungi are the most common agents producing life-threatening invasive mycoses it has been estimated that 200,000 immunocompromised patients develop invasive aspergillosis (IA) annually.

The commonest fungal genus to cause pulmonary-associated fungal infections is Aspergillus Fumigatus, with a wide spectrum of syndromes spanning allergic disease, saprophytic invasion (fungal bronchitis), and invasive aspergillosis.

Despite wide availability of antifungal therapies for invasive aspergillosis, mortality rates remain extremely high. Diagnosis is difficult and conventional therapies have dose-limiting toxicities. Experimental studies using inhaled Voriconazole and Amphotericin in small patient populations have provided promising data for the inhaled concept. An opportunity exists to identify a new generation of potent inhaled therapies that have been optimized for lung administration.

Find out more about the products we are developing to treat invasive lung infections

Respiratory Syncytial Virus

Pulmonary Aspergillosis

Chronic Pulmonary Aspergillosis

Chronic forms of pulmonary aspergillosis consist of simple aspergilloma, chronic cavitary pulmonary aspergillosis (CCPA), and chronic necrotizing pulmonary aspergillosis (CNPA) are estimated to affect ~1M patients worldwide

globe 0M
Patients Affected Worldwide

Allergic bronchopulmonary aspergillosis (ABPA)

ABPA is a pulmonary disorder caused by hypersensitivity to Aspergillus Fumigatus. Allergic fungal airways disease (AFAD) includes patients in which IgE sensitization and associated airway colonization with A. fumigatus, associated with poor disease control. AFAD is estimated to occur in 50% of patients with severe asthma.

Up to 48% of the adult cystic fibrosis population have ABPA or Aspergillus bronchitis (17,989 adults)

Armstead J, Morris J, Denning DW (2014) Multi-Country Estimate of Different Manifestations of Aspergillosis in Cystic Fibrosis. PLoS ONE 9(6): e98502

globe 0.0M
There are estimated to be 4.8 million adults with allergic bronchopulmonary aspergillosis (ABPA) complicating asthma.

Denning et al. Clinical and Translational Allergy 2014, 4:14 Armstead, Plos 1 June 2014 | Volume 9 | Issue 6

Acute invasive aspergillosis

Invasive infection is a life-threatening infection caused by Aspergillus in patients with prolonged neutropenia or immunosuppression. Immuno-compromised patients, such as those undergoing stem cell or solid-organ transplantation, or those undergoing intensive treatment for haematological cancer, are at particular risk.

About 1-2% of COPD patients admitted to hospital have invasive aspergillosis (60,000 IA cases). Filamentous fungi were recently cultured in 49% of COPD patients , 75% of which were A. fumigatus.

people image 0K
Over 200,000 patients develop invasive aspergillosis annually

Bafadehl et al Eur Respir J 2014; 43: 64–71